Related Experiment Videos
Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines
S Saito1, R Bannerji, B Gansbacher
1Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Abstract:
This study explored the use of cytokine gene-modified tumor cells as cellular vaccines for the treatment of bladder cancer. The mouse MBT-2 tumor is an excellent model for human bladder cancer. This carcinogen-induced tumor of bladder origin resembles human bladder cancer in its etiology and histology and responds to treatment in a manner similar to that of its human counterpart. In a previous study we have shown that interleukin 2 (IL-2)-secreting, irradiated, MBT-2 cell preparations were capable of curing animals from orthotopically established tumors and engendered protective immunological memory in the cured animals. In this study we have compared the effectiveness of several cytokines and found that while IL-1 alpha, IL-1 beta, and gamma-interferon were only weakly effective in the therapeutic vaccination protocol, granulocyte-macrophage colony-stimulating factor was almost as effective as but not superior to IL-2, as reported previously for another tumor model system. Induction of cytotoxic T-lymphocyte correlated only poorly with the therapeutic benefit of the cytokine gene-modified tumor cell preparations, questioning its prognostic value for the development of improved genetically modified tumor vaccines.
Insights
This study investigated cytokine gene-modified tumor cells for bladder cancer treatment. Granulocyte-macrophage colony-stimulating factor showed effectiveness comparable to interleukin-2, but other cytokines were less successful.
Area of Science:
- Oncology
- Immunology
- Cancer Vaccines
Background:
- Bladder cancer treatment remains a significant challenge.
- Cytokine gene-modified tumor cells offer a promising avenue for cellular immunotherapy.
- The MBT-2 mouse tumor model closely mimics human bladder cancer characteristics.
Purpose of the Study:
- To compare the efficacy of various cytokines in gene-modified cellular vaccines for bladder cancer.
- To evaluate the therapeutic potential of granulocyte-macrophage colony-stimulating factor (GM-CSF) against IL-2.
- To assess the correlation between T-lymphocyte induction and therapeutic outcomes.
Main Methods:
- Utilizing the MBT-2 mouse bladder cancer model.
- Developing irradiated, cytokine gene-modified tumor cell vaccines.
- Comparing the therapeutic effects of IL-1 alpha, IL-1 beta, gamma-interferon, IL-2, and GM-CSF.
- Monitoring tumor regression and immunological memory.
Main Results:
- Granulocyte-macrophage colony-stimulating factor (GM-CSF) demonstrated significant therapeutic efficacy, comparable to but not superior to interleukin-2 (IL-2).
- Interleukin-1 alpha, IL-1 beta, and gamma-interferon showed limited effectiveness in the therapeutic vaccination protocol.
- The induction of cytotoxic T-lymphocytes showed a poor correlation with the therapeutic benefits observed.
Conclusions:
- GM-CSF is a viable cytokine for enhancing cellular cancer vaccines in bladder cancer models.
- IL-2 remains a highly effective cytokine for this therapeutic approach.
- The predictive value of cytotoxic T-lymphocyte induction for vaccine efficacy requires further investigation.